Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement

Yonsei University

Overview

According to TEG (thromboelastography), as maximum amplitude is increased the amount of bleeding and transfusion and Cardiac enzyme is reduced by using ulinastatin.

Study Type

INTERVENTIONAL

Conditions

Abnormal Aortic Valve

Interventions

ulinastatinDRUG

Administer 30000U/ulinastatin. Comparison of different dosages of drug.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 40% below of output of left ventricle * tricuspid valve failure from moderate to severe * urgent surgery required * infectious endocarditis

Locations (1)

Severance Hospital

Seoul, South Korea

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.